The degree to which rheumatoid arthritis (RA) influences life expectancy and the causes of death is the subject of a number of reports. Some16 indicate that patients with RA have a reduced life expectancy as a result of the disease. Others,7 8 analysing the causes of death, distinguish between deaths attributable in some way to RA and deaths unrelated to it. Thus, Eulderink7 found that among 111 deaths approximately 1 in 5 were related to the arthritis and 1 in 8 to its treatment. Similarly, Constable et al.8 found among 100 deaths proportions of 1 in 6 and 1 in 4 respectively.
All of these reports, however, are open to bias in that they are based on patients admitted to hospital with established disease. They may therefore be dealing with selected patients suffering from relatively complicated forms ofRA.
The present study is based on a series of 100 patients with RA seen initially by J.A.C. within a year of the onset of their disease, and followed up now for 18 years. Forty-three of the 100 have now died.
We here review the causes of their deaths and the degree to which rheumatoid disease caused or contributed to death. We have also reviewed clinical and laboratory data recorded 1 year after the onset of arthritis to see what idications they might give of the eventual cause and date of death.
Patients and methods
All of the patients had, by definition, either definite or classical RA by the ARA criteria within 1 year of onset. They formed a consecutive series, without selection, in that all patients who were referred to J.A.C. and who met the above criteria for RA of recent onset were accepted into the series. There were 36 men and 64 women, of ages ranging from 18 to 81 years at onset (mean 50.6), and the average duration of RA when first seen was 3.7 months. 9 10 Contact has been maintained with all 57 surviving patients, and the cause of death is known in the 43 who have died.
Information on each patient's condition 1 year after the onset of RA was available for analysis as follows: clinical details of the arthritis, number of affected joints (joint score), the presence of nodules, grading of disease by ARA criteria,"1 functional capacity.12 Laboratory investigations included haemoglobin ESR (Westergren), and Rose-Waaler titre. Further details of the 100 patients, the onset of their arthritis, and their state 11 years after onset are given elsewhere.9 After 11 years 17 patients had died, and in S of these it was considered that RA had caused or contributed to death. 115
A review was made of the surviving patients in 1979 when the average duration of arthritis was 18 years. Information about those who had died was brought up to date. The cause and circumstances of death were known in all 43. Many were seen personally in their final illnesses and 16 had necropsies. Information was available on the remaining deaths through hospital records or through general practitioners in the case of those who died at home.
The deaths were classified into 3 groups: deaths directly due to RA and its systemic complications ('attributable'), deaths due to other causes, but with RA or its treatment as a contributory factor ('contributory'), and deaths from causes unrelated to RA ('unrelated'). A fourth group consisted of the 57 survivors.
Results

CAUSE OF DEATH
The three groups and the causes of death are summarised in the first three Tables.
'Attributable' deaths. In Table 1 are listed the 9 patients whose deaths were directly attributable to rheumatoid disease. Three, cases 5, 7, and 8, died from renal failure due to amyloid disease, confirmed at necropsy and attributed to the rheumatoid disease. Two, cases 4 and 9, died from rheumatoid heart disease (one of them postoperatively), which was confirmed at necropsy. Four had vasculitis with infarctions and other lesions as a result, but only 1 had a necropsy, case 2. Case 1, for whom necropsy was refused, suffered peripheral vasculitic lesions, malignant hypertension, renal failure, and died with a probable mesenteric occlusion. Case 3, for whom necropsy was refused, had severe vasculitis, and gangrenous lesions of feet. Case 6, with rapidly progressive seropositive RA had vasculitis with mononeuritis and polyneuritis, and while suffering from this developed total heart block. No pacemaker service was then available (1961), and he died at home some months later in a Stokes-Adams attack. Although necropsy confirmation was lacking, heart block was attributed to rheumatoid heart disease in view of the current activity of the vasculitis rather than to degenerative disease of the conducting tissue. 'Contributory' deaths. Table 2 shows the 7 patients in whom rheumatoid disease or its treatment contributed to death without being its primary cause. In 6 of these drug therapy was considered to be a contributory factor. Patient 2 died of reticulosarcoma within a year of starting azathioprine therapy.14 15 Patients 3 to 7 were receiving corticosteroids, and this contributed to the infection which brought about their deaths. Patient 1 died of septicaemia after hip arthroplasty; diabetes was a contributory factor as well as the RA for which operation was performed. Necropsies were performed in 4 of the 7.
'Unrelated' deaths. Table 3 summarises the causes Comparisons of the age at death in the three groups is also shown in Table 4 . The age at death from unrelated causes, 71-9 years, is significantly higher than that for the attributable deaths (60.4) or for attributable and contributory deaths combined (63*7).
RELATIONSHIP WITH FEATURES OF THE EARLY STAGES OF RA
We now turned to the data available on individual patients 1 year after the onset of their arthritis to see what differences could be found at that early stage between patients in the three groups, and the survivors.
Sex differences. Overall, there were relatively more deaths among men (19/36 or 53%) than among women (24/64 or 37' 5%). This difference did not reach statistical significance, either overall or within individual groups. However, as a result of the higher proportion of deaths in men the sex ratio of the survivors is now more predominantly female (2-4 :1) than it was in the original 100 patients (1-8 :1).
In the group with 'unrelated' deaths, the ARA grading at one year was worse for women than for men, but this did not reach statistical significance.
ARA grading. The American Rheumatism Association (ARA) grading after one year of arthritis is shown in Table 5 for the different groups. In all, (Table 5 ). The cumulative death rates for patients in these 2 classes over the 18 or so yeats of follow-up are shown in Fig. 1 . The worse death rate in the 'classical' patients became more manifest after the 10th year. The mortality now stands at 54% (28/52) for the 'classical' compared with 31 % (15/48) for the 'definite' grade patients: a highly significant difference (P=0 01).
Patients in these 2 classes are comparable in their mean age of onset (51 25 years for the 'classical' and 49 9 for the 'definite'). However, Table 5 shows that the 'classical' grade patients had a high proportion of deaths related to RA (14/28), whereas 'definite' grade patients only had 2 out of 15.
Corticosteroid treatment. Forty-nine of the 100 patients were treated with corticosteroids in the early stages of their arthritis, and some of the survivors continue on a low dosage now. We compared the frequency of corticosteroid treatment in 4 groups. Also the 'attributable' group differed significantly from 'unrelated' group and survivors (P 0.001). Fig. 1 The cumulative death rate from all causes is shown during the follow-up periodfor the 2 grades of 'definite' and 'classical' RA. Grading was made after 1 year ofarthritis. The 2 grades are nearly equal in number (48 'definite' and 52 'classical') and in age of onset (means of49 9 and 51 25 years respectively), but the finalfigures for deaths are significantly different (P=0 01). Table 7 shows that the 'attributable' and 'contributory' groups combined had a significantly higher incidence of corticosteroid treatment than the other groups. This is due to the former groups of patients having more serious disease and stronger indications for the use of corticosteroids.
YEARS deaths
We found no association between corticosteroid treatment and deaths from cardiovascular disease. Thus, in the 'unrelated' group strokes and cardiac infarcts caused death in 10 of the 11 patients given corticosteroids, and in 10 of the 16 patients not so treated; not a significant difference.
Discussion
We consider that our analysis of the causes of death in RA represents the true state of affairs in that our 100 patients were first seen early in their disease, mainly as referrals to clinics, not necessarily admitted to hospital, and followed up for some 18 years. All, within a year of onset, met the criteria for 'definite' or 'classical' RA and were an otherwise unselected series. Other reported analyses are less truly representative in that they are based on patients already admitted to hospital with established RA1 3 4 or include 'probable' RA patients5 6 or are simply a review of deaths in hospital of patients having RA. 8 Nevertheless, our results are little different from those of other reports; Table 8 , comparing our series with 3 others, shows remarkable similarities. However, our patients had an older mean age of death, 69 years, compared with 63 in each of the other 3 series. Our patients also had an older mean age of onset, 50-6 years, compared with 45 years in Reah's patients. 3 We noted a higher overall mortality in men than in women (53% and 37 5% respectively over 18 years). This is a general finding," and here Reah's figures are very close to our own (54 % and 39 %), though occurring in the shorter period of 13 years. The long-term effect of this higher male mortality is to increase the female preponderance in patients with long-standing RA. In this way the female: male ratio in our patients rose from 18 :1 in the 100 patients at onset to 2-4 1 in the survivors 18 years later.
We found that patients whose deaths were due to or related to RA had a younger age of onset and a younger age of death than those whose deaths were unrelated to RA. Certainly the former had more serious disease than the others as indicated by their worse ARA grading and worse functional capacity after 1 year of arthritis. Surprisingly, the more serious nature of their disease was not reflected in the figures for ESR, haemoglobin, or Rose-Waaler titre at that early stage.
As might be expected, the presence of additional criteria of disease in patients with 'classical' RA has a harmful long-term effect on prognosis and survival. This is well shown in the cumulative death rates charted in Fig. 1 On this basis we suggest that the generally agreed reduction of life span in patients with RA is mainly 
